A type of immune cell that has received little attention in multiple sclerosis (MS) research may play a key role in driving the disease. A study found that some people with MS had abnormally high levels of virus-fighting CD8 T-cells in the fluid surrounding the brain and spinal cord.
A clinical trial testing TG Therapeutics‘ CD20 inhibitor Briumvi (ublituximab-xiiy) in children with relapsing forms of multiple sclerosis (MS) will begin enrolling participants within the next few months, the developer announced, also unveiling details of the study’s design. The upcoming Phase 2/3 trial (NCT07220252) will run…
Discussion
It took exactly 14 days for my health insurance to pick the first fight with me this year. The letter arrived quietly, the way these things always do. Denied. Out of network. This time it was Octave Bioscience’s Multiple Sclerosis Disease Activity (MSDA) test, a blood test that evaluates…
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Discussion
Like many of my peers in the military, I developed the ability to fall asleep in any position or place and at any time that I wasn’t actively engaged in something. On one occasion, during a particularly loud and turbulent flight, I managed to stay awake just long enough to…
Get regular updates to your inbox.
